Q-omics provides the consensus-scored LUC7L3 profile across patient tissues and cancer cell-line models. LUC7L3 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, LUC7L3 is differentially expressed in 13, with the highest sampling consensus in LIHC. Additionally, LUC7L3 protein abundance shows 32,055 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BLCA, LIHC, and GBM as cancer lineages where LUC7L3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LUC7L3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LUC7L3 survival associations across molecular data types. LUC7L3 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LUC7L3 RNA expression–survival associations across cancer types. High LUC7L3 expression shows unfavorable associations in KIRC, LIHC, ACC, KICH and UVM, but favorable associations in BLCA. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for LUC7L3 RNA expression.
This table summarizes LUC7L3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in LIHC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for LUC7L3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LUC7L3 shows lower tumor expression in KICH and higher tumor expression in LIHC, HNSC, STAD, BLCA and COAD. The LIHC box plot shows higher LUC7L3 RNA expression in tumor versus normal tissue (log2 FC = +1.184, t-test p < 0.001).
This table shows molecular features associated with LUC7L3 in patient tissues and cancer cell lines. In patient samples, LUC7L3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, LUC7L3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Leukemia.
